Literature DB >> 25288779

IL-17-producing CD4+ T cells are increased in early, active axial spondyloarthritis including patients without imaging abnormalities.

Diahann T S L Jansen1, Marjolijn Hameetman1, Jeroen van Bergen1, Tom W J Huizinga1, Désirée van der Heijde1, René E M Toes1, Floris A van Gaalen2.   

Abstract

OBJECTIVE: Increased numbers of IL-17-producing CD4(+) T cells have been observed in AS. However, it is not known whether these CD4(+) T cells are already present in early disease or if this is a late disease phenomenon only. Therefore we aimed to investigate whether IL-17-producing CD4(+) T cells are involved in early active axial SpA, including patients without imaging abnormalities, by determining the frequency and phenotype of IL-17-producing CD4(+) T cells in these patients.
METHODS: Flow cytometry was used to analyse cytokine production and surface marker expression of peripheral blood mononuclear cells from 31 patients suffering from early active HLA-B27-positive axial SpA fulfilling the Assessment of SpondyloArthritis International Society criteria with or without MRI abnormalities and 21 healthy controls.
RESULTS: Patients with early active axial SpA showed an increased percentage of IL-17-producing CD4(+) T cells compared with healthy controls (mean 1.1% vs 0.4%, respectively; P = 0.013). The percentage of IL-17-producing CD4(+) T cells was equally increased in patients with and without MRI abnormalities (1.2% vs 1.1%, respectively; P = 0.81). These IL-17-producing CD4(+)T cells expressed the αβ T cell receptor but not the γδ T cell receptor, exhibited a memory phenotype and expressed CD161, but only sporadically expressed killer cell immunoglobulin-like receptor 3DL2 (KIR3DL2).
CONCLUSION: IL-17-producing CD4(+) T cells are increased in patients with early active axial SpA both with and without MRI abnormalities. This finding shows that the frequency of IL-17-producing CD4(+) T cells is enhanced in the early stages of disease.
© The Author 2014. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  CD4+ T cells; IL-17; KIR; ankylosing spondylitis; axial spondyloarthritis

Mesh:

Substances:

Year:  2014        PMID: 25288779     DOI: 10.1093/rheumatology/keu382

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  21 in total

Review 1.  Genetics and the Causes of Ankylosing Spondylitis.

Authors:  Aimee Hanson; Matthew A Brown
Journal:  Rheum Dis Clin North Am       Date:  2017-08       Impact factor: 2.670

Review 2.  The Bench-to-Bedside Story of IL-17 and the Therapeutic Efficacy of its Targeting in Spondyloarthritis.

Authors:  Judith A Smith
Journal:  Curr Rheumatol Rep       Date:  2016-06       Impact factor: 4.592

Review 3.  IL-23 responsive innate-like T cells in spondyloarthritis: the less frequent they are, the more vital they appear.

Authors:  Koen Venken; Dirk Elewaut
Journal:  Curr Rheumatol Rep       Date:  2015-05       Impact factor: 4.592

Review 4.  Targeting the interleukin-23/17 axis in axial spondyloarthritis.

Authors:  Ananta Paine; Christopher T Ritchlin
Journal:  Curr Opin Rheumatol       Date:  2016-07       Impact factor: 5.006

Review 5.  Beyond the TNF-α Inhibitors: New and Emerging Targeted Therapies for Patients with Axial Spondyloarthritis and their Relation to Pathophysiology.

Authors:  Susanne Juhl Pedersen; Walter P Maksymowych
Journal:  Drugs       Date:  2018-09       Impact factor: 9.546

Review 6.  The Pathogenesis of Ankylosing Spondylitis: an Update.

Authors:  Susanne Juhl Pedersen; Walter P Maksymowych
Journal:  Curr Rheumatol Rep       Date:  2019-11-11       Impact factor: 4.592

Review 7.  Barrier lymphocytes in spondyloarthritis.

Authors:  Adam Berlinberg; Kristine A Kuhn
Journal:  Curr Opin Rheumatol       Date:  2020-07       Impact factor: 5.006

8.  Immune cell transcript modules reveal leukocyte heterogeneity in synovial biopsies of seronegative spondylarthropathy patients.

Authors:  Robin M Hallett; Tracy Chew
Journal:  BMC Musculoskelet Disord       Date:  2014-12-19       Impact factor: 2.362

9.  Anti-IL17A in Axial Spondyloarthritis-Where Are We At?

Authors:  Peter P Cheung
Journal:  Front Med (Lausanne)       Date:  2017-01-18

10.  The genetic association of RUNX3 with ankylosing spondylitis can be explained by allele-specific effects on IRF4 recruitment that alter gene expression.

Authors:  Matteo Vecellio; Amity R Roberts; Carla J Cohen; Adrian Cortes; Julian C Knight; Paul Bowness; B Paul Wordsworth
Journal:  Ann Rheum Dis       Date:  2015-10-09       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.